Life-changing drugs must be an NHS priority

THE regulatory approval of cystic fibrosis "wonder drug” Alyftrek, which has been shown to make most symptoms of the life-limiting genetic disorder “vanish”, is a potent reminder why the health service must prioritise quality of life over red tape and penny pinching.

- 

Such next-generation medicines can transform the lives of millions across a wide range of conditions, cutting medical costs and allowing patients to live more fulfilling, economically-active lives. But only if the NHS can afford them in the first place.